Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors

We have performed a study using cell lines established from biopsies of clinically resistant non-small cell lung cancers with the aim of discovering therapeutic strategies to overcome acquired resistance. Our results indicate that pharmacological assessment of tumor material might efficiently comple...

Descripción completa

Detalles Bibliográficos
Autor principal: Benes, Cyril H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905366/
https://www.ncbi.nlm.nih.gov/pubmed/27308520
http://dx.doi.org/10.1080/23723556.2014.999504
_version_ 1782437254069747712
author Benes, Cyril H
author_facet Benes, Cyril H
author_sort Benes, Cyril H
collection PubMed
description We have performed a study using cell lines established from biopsies of clinically resistant non-small cell lung cancers with the aim of discovering therapeutic strategies to overcome acquired resistance. Our results indicate that pharmacological assessment of tumor material might efficiently complement genetic profiling in the future path toward personalized medicine.
format Online
Article
Text
id pubmed-4905366
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49053662016-06-15 Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors Benes, Cyril H Mol Cell Oncol Author's View We have performed a study using cell lines established from biopsies of clinically resistant non-small cell lung cancers with the aim of discovering therapeutic strategies to overcome acquired resistance. Our results indicate that pharmacological assessment of tumor material might efficiently complement genetic profiling in the future path toward personalized medicine. Taylor & Francis 2015-05-01 /pmc/articles/PMC4905366/ /pubmed/27308520 http://dx.doi.org/10.1080/23723556.2014.999504 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Benes, Cyril H
Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
title Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
title_full Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
title_fullStr Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
title_full_unstemmed Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
title_short Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
title_sort direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905366/
https://www.ncbi.nlm.nih.gov/pubmed/27308520
http://dx.doi.org/10.1080/23723556.2014.999504
work_keys_str_mv AT benescyrilh directpharmacologicalassessmentofclinicallyacquiredmodelsasastrategytoovercomeresistancetotyrosinekinaseinhibitors

Ejemplares similares